Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey.

IF 5.1 2区医学 Q1 ONCOLOGY Prostate Cancer and Prostatic Diseases Pub Date : 2024-10-21 DOI:10.1038/s41391-024-00909-w

Alessandro Uleri, Jean Nicolas Cornu, Benjamin Pradere, Thomas R W Herrmann, Vincent Misrai, Morgan Roupret, Cosimo De Nunzio, Hashim Hashim, Guillaume Ploussard, Michael Baboudjian

{"title":"Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey.","authors":"Alessandro Uleri, Jean Nicolas Cornu, Benjamin Pradere, Thomas R W Herrmann, Vincent Misrai, Morgan Roupret, Cosimo De Nunzio, Hashim Hashim, Guillaume Ploussard, Michael Baboudjian","doi":"10.1038/s41391-024-00909-w","DOIUrl":null,"url":null,"abstract":"Background: To explore how urologists manage prostate cancer (PCa) screening and treatment in patients undergoing endoscopic enucleation of the prostate (EEP).Methods: A team of experts in EEP collaboratively formulated the survey questions through an interactive process. The survey opened in January 2024 and closed in February 2024.Results: 102 urologists responded, revealing that most use PSA and digital rectal examination for screening, with high PSA and abnormal DRE prompting prostate MRI. 75% perform pre-EEP biopsies. For incidental low-grade PCa, active surveillance is preferred. For intermediate-grade PCa, most use PSA and MRI for workup, often choosing active surveillance if post-EEP biopsies are negative. There's no consensus on abnormal post-operative PSA thresholds.Conclusions: While urologists are aware of PCa management in EEP candidates, future work should focus on developing optimal post-EEP screening protocols.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-024-00909-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To explore how urologists manage prostate cancer (PCa) screening and treatment in patients undergoing endoscopic enucleation of the prostate (EEP).

Methods: A team of experts in EEP collaboratively formulated the survey questions through an interactive process. The survey opened in January 2024 and closed in February 2024.

Results: 102 urologists responded, revealing that most use PSA and digital rectal examination for screening, with high PSA and abnormal DRE prompting prostate MRI. 75% perform pre-EEP biopsies. For incidental low-grade PCa, active surveillance is preferred. For intermediate-grade PCa, most use PSA and MRI for workup, often choosing active surveillance if post-EEP biopsies are negative. There's no consensus on abnormal post-operative PSA thresholds.

Conclusions: While urologists are aware of PCa management in EEP candidates, future work should focus on developing optimal post-EEP screening protocols.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

前列腺癌筛查和前列腺内窥镜去核术候选患者的管理：一项国际调查。

背景：探讨泌尿科医生如何管理接受内窥镜前列腺去核术（EEP）患者的前列腺癌（PCa）筛查和治疗：探讨泌尿科医生如何管理接受前列腺内窥镜切开术（EEP）患者的前列腺癌（PCa）筛查和治疗：由 EEP 专家组成的团队通过互动过程共同制定了调查问题。调查于 2024 年 1 月开始，2024 年 2 月结束：102名泌尿科医生对调查做出了回复，结果显示大多数医生使用PSA和数字直肠指诊进行筛查，PSA高和数字直肠指诊异常时会进行前列腺磁共振成像检查。75%的医生会进行EEP前活检。对于偶发的低级别 PCa，首选积极监测。对于中度 PCa，大多数人使用 PSA 和 MRI 进行检查，如果 EEP 术后活检结果为阴性，通常会选择积极监控。对于术后 PSA 异常的阈值，目前尚未达成共识：尽管泌尿科医生已经意识到了EEP候选者的PCa管理问题，但未来的工作重点应放在制定最佳的EEP术后筛查方案上。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学

CiteScore

10.00

自引率

6.20%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.